We have commissioned four scientists, who together have well over 147 Patents in inhalation related work, to develop heat-generated aerosol inhalers. These four scientists have 137 years experience in developing inhalation devices and aerosolizing compounds.  

DOES, Inc. has been developing inhalers for pulmonary ingestion of drugs since 1985.

We  are looking for a partner to continue development of a 'new unique inhaler' that no one else has.

a) the new unique device produces Heat Generated Drug Delivery Aerosols (HGDDA) that aerosolizes pharmaceuticals for inhalation with the following advantages:

      1)  does not cause degradation (decomposition) of the drug
      2)  will deliver your required particle size,  MMAD .2 to 3 microns or smaller
      3)  solves the agglomeration problem
      4)  delivers a precise drug dosage
      5)  has thermostatically controlled temperature
      6)  expected to deliver 60-90% of the drug
      7) delivers little or no pyrolysis degradation compounds 

b) We have developed the important materials to effectively deliver an aerosol generated by the aerosolization device described above. 

c) We have experience with many drug carriers to insure effective drug delivery.

d) Working with your people, we can configure this device to deliver each drug quantity; using the proper temperature, with the required particle size delivered. 

e) Our product pipeline includes:

    1)   a miniaturized drug vaporization device (HGDDA) approximately 1" by 4" in size that uses heat to generate           an aerosol that can be inhaled - with the above advantages numbered 1), 2), 3), 4), 5),6, and 7).
    2)   an active DPI device that will deliver combination drugs.
    3)   an add on device that will increase the efficiency of current inhaler devices. This add on device can be used           for many inhaled drugs.
    4)   A passive DPI device that will deliver combination drugs.